ArticleJournal of cosmetic dermatology2026
Enhanced Effectiveness of Onabotulinum Toxin A in Combination With Definisse KP1 Eye Contour Cream for Upper Face Rejuvenation: A Case Series.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmong antiaging treatments, botulin toxin A injection is one of the most widely used. KP1 (Serpine A1-III) is a recently developed bioactive peptide that increases collagen type I by enhancing its synthesis and preventing its degradation.
aimsThis case series described the combinatorial effect of onabotulinum toxin A injection with Definisse KP1 eye contour cream application in the treatment of skin aging in the upper third of the face. PATIENTS/
methodsAdult subjects with moderate to severe dynamic wrinkles who received onabotulinum toxin A combined with Definisse KP1 eye contour cream (Onabotulinum toxin A + KP1 group, hereinafter referred to as + KP1 group) or onabotulinum toxin A alone (Control group) were included in the analysis. The following variables were measured: severity of the disorder, skin hypersensitivity, erythema, oedema, periocular wrinkles, skin quality, hydration-creepiness, and tightness; each parameter was evaluated in both eyes 4 weeks posttreatment.
resultsData from 22 in the + KP1 group and 19 in the Control group were collected. In the + KP1 group, all variables improved, except for eye erythema and eye oedema. Conversely, in the Control group, only eye impairment severity and periocular wrinkles improved from baseline. In the satisfaction questionnaire, the overall evaluation of the protocol achieved higher scores in the + KP1 group than in the Control group.
conclusionsFrom this case series, the application of Definisse KP1 eye contour cream seems to enhance the effect of onabotulinum toxin A injection on periocular wrinkles and provide additional benefits in skin quality; the combined procedure was tolerated, feasible, and appreciated by subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.